HER2 gene amplification has been reported in 10–35% of invasive breast carcinomas, and it is associated with an aggressive disease course, increased disease recurrence, and decreased disease-free and overall survival in lymph node-positive patients [2-5]. This evidence concerns the gene ERBB2 and invasive breast carcinoma.